Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STADOL vs ORAMORPH SR
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Partial agonist at mu-opioid receptors and agonist at kappa-opioid receptors in the CNS, altering pain perception and emotional response to pain.
Morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. Binding to mu-opioid receptors in the central nervous system (CNS) and peripheral tissues results in analgesia, euphoria, sedation, respiratory depression, and physical dependence. Morphine also activates descending inhibitory pathways and inhibits ascending nociceptive transmission.
Moderate to severe pain,Preoperative sedation,Supplement to balanced anesthesia
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: treatment of dyspnea in patients with advanced illness, management of opioid withdrawal symptoms (limited use)
Butorphanol tartrate 1-2 mg IV or IM every 3-4 hours as needed for pain; alternatively, 0.5-1 mg IV every 3-4 hours. For nasal spray: 1 mg (one spray) in one nostril, may repeat in 60-90 minutes if needed; then 1 mg every 3-4 hours as needed.
10-30 mg orally every 8-12 hours, sustained-release; titrate as needed for pain.
Terminal elimination half-life: 2.5-4 hours; clinically, prolonged in hepatic impairment (up to 10-12 hours) and elderly
2–4 hours in adults; in controlled-release formulation, effective half-life is prolonged due to sustained absorption. Clinically, steady-state is achieved in 1–2 days.
Primarily hepatic via CYP3A4 and conjugation; forms active metabolite (pentazocine) and inactive metabolites.
For creatinine clearance (Cr Cl) < 30 m L/min: reduce dose to half the usual recommended dose and increase dosing interval to every 6-8 hours. For Cr Cl 30-50 m L/min: consider extending interval to every 6 hours. Avoid use in severe renal impairment (Cr Cl < 15 m L/min) if possible.
GFR 10-50 m L/min: administer 75% of usual dose every 12 hours; GFR <10 m L/min: administer 50% of usual dose every 12 hours.
Risk of respiratory depression, especially in elderly, cachectic, or debilitated patients. Risk of opioid addiction, abuse, and misuse. Life-threatening respiratory depression can occur at any time. Accidental ingestion, especially in children, can be fatal. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.
FDA Category C/D (if used for prolonged periods or high doses near term). First trimester: Limited data; potential risk of congenital malformations not definitively established; avoid if possible. Second trimester: Use only if clearly needed; no well-documented teratogenicity. Third trimester: Use may cause neonatal withdrawal syndrome (irritability, crying, tremors, hypertonia, seizures) and respiratory depression if given near delivery; prolonged use may lead to physical dependence in fetus.
First trimester: Limited human data, but animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to fetal dependence and neonatal withdrawal syndrome (neonatal abstinence syndrome); use only if clearly needed. Risk of preterm labor and low birth weight with prolonged use.
Stadol (butorphanol) is a mixed agonist-antagonist opioid; use with caution in opioid-dependent patients as it may precipitate withdrawal. Administer intranasally for rapid onset; ensure proper patient positioning to avoid falls due to dizziness. Monitor respiratory depression, especially in elderly or those with COPD.
Oramorph SR is a sustained-release morphine formulation for chronic pain; do not crush or chew tablets. Onset is delayed; use immediate-release opioids for breakthrough pain. Equianalgesic dosing: 30 mg oral morphine ≈ 10 mg parenteral morphine. Monitor for respiratory depression, especially in opioid-naive patients. Avoid in patients with GI obstruction or acute asthma. Taper upon discontinuation to prevent withdrawal.
No interactions on record
No interactions on record
STADOL and ORAMORPH SR are distinct pharmacological agents. STADOL belongs to the Opioid Analgesic class and is primarily used for Moderate to severe painPreoperative sedationSupplement to balanced anesthesia. ORAMORPH SR belongs to the Opioid Analgesic class and is primarily used for Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequateOff-label: treatment of dyspnea in patients with advanced illness, management of opioid withdrawal symptoms (limited use). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. STADOL carries a safety status of Category C, whereas ORAMORPH SR safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily metabolized via glucuronidation in the liver to morphine-3-glucuronide (M3G, major inactive metabolite) and morphine-6-glucuronide (M6G, active metabolite with analgesic and respiratory depressant effects). Minor metabolism via sulfation. Involved enzymes: UGT2B7 (primary), UGT1A1, UGT1A3, UGT1A8. CYP450 enzymes play a minimal role.
Renal: 85-90% as unchanged drug and metabolites (primarily as glucuronide conjugates); Fecal: <10%; Biliary: minimal
Renal (approximately 90% as morphine-3-glucuronide and morphine-6-glucuronide, minor amounts of unchanged morphine, and other conjugates); biliary/fecal (approximately 10%).
80-85% bound primarily to albumin, also to alpha-1-acid glycoprotein
30–35% bound, primarily to albumin.
3-5 L/kg; large Vd indicates extensive tissue distribution, with CNS penetration
3–5 L/kg (large Vd indicates extensive tissue distribution, including sequestration in skeletal muscle and fat).
Intramuscular: ~80%; Oral: ~17% (poor oral bioavailability due to extensive first-pass metabolism)
Oral (immediate-release): 20–40% (first-pass metabolism); Oral (controlled-release): approximately 15–30% (slightly lower due to slow release formulation).
In Child-Pugh Class B (moderate impairment): reduce initial dose by 50% and titrate cautiously. For Child-Pugh Class C (severe impairment): avoid use or use with extreme caution, using the lowest effective dose; consider alternative therapy. No specific dose adjustment for Child-Pugh A.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: reduce dose by 75% or consider alternative.
Not recommended for use in children < 18 years of age due to lack of safety and efficacy data. For adolescents (if used): 0.5-1 mg IV/IM every 3-4 hours as needed, based on weight (0.01-0.02 mg/kg/dose); maximum 2 mg per dose. Nasal spray not recommended.
0.2-0.4 mg/kg/dose orally every 12 hours as sustained-release; maximum 1 mg/kg/dose; not recommended for children <6 months.
In patients > 65 years: initial dose should be reduced to 0.5 mg IV/IM every 4-6 hours, and titrate slowly due to increased sensitivity and risk of respiratory depression. For nasal spray: initial 1 mg, then extended interval (every 4-6 hours) and monitor closely. Maximum single dose: 1 mg IV/IM.
Start at the low end of dosing range (e.g., 10 mg every 12 hours) and titrate cautiously due to increased sensitivity and risk of respiratory depression; consider renal function.
Respiratory depression, CNS depression, dependency, opioid-induced hyperalgesia, increased intracranial pressure, biliary tract spasm, seizure risk, severe hypotension, adrenal insufficiency, androgen deficiency.
Hypersensitivity to butorphanol or tartrazine, use of MAOIs within 14 days, severe asthma or respiratory insufficiency, gastrointestinal obstruction, suspected surgical abdomen.
No specific food interactions. Avoid grapefruit juice as it may alter drug metabolism. Take with or without food; nausea may be reduced with food.
Avoid alcohol; may potentiate CNS depression. No specific food restrictions, but high-fat meals may delay absorption. Maintain adequate fluid and fiber intake to prevent constipation.
Butorphanol is excreted into breast milk; M/P ratio is approximately 0.7 – 1.0. Concentrations are low but may cause sedation or respiratory depression in the infant; AP rated by AAP as 'maternal medication usually compatible with breastfeeding' with caution. Monitor infant for drowsiness, feeding difficulty, or respiratory depression.
Morphine is excreted into breast milk with M/P ratio approximately 2.5. Monitor infant for respiratory depression and withdrawal. Doses up to 30 mg/day orally are considered compatible with breastfeeding, but higher doses or chronic use require caution.
No specific dose adjustment recommended for pregnancy; however, pharmacokinetic changes (increased volume of distribution, increased clearance) may require dose titration to effect. Use lowest effective dose and shortest duration; consider reduced doses in obese patients or those with renal/hepatic impairment.
No routine dose adjustment is recommended; however, increased clearance in pregnancy may require higher doses to achieve analgesia. Taper gradually to avoid withdrawal. Epidural or intrathecal administration preferred for labor analgesia.
Do not drink alcohol while using Stadol; it can increase dizziness and drowsiness.,Avoid driving or operating heavy machinery until you know how Stadol affects you.,Use the nasal spray exactly as prescribed; do not share with others.,Inform your doctor of all medications you take, especially other opioids, sedatives, or antidepressants.,Do not stop suddenly; withdrawal symptoms may occur.
Swallow tablets whole; do not crush, chew, or dissolve.,Take exactly as prescribed; do not increase dose without consulting doctor.,Avoid alcohol and other CNS depressants.,May cause drowsiness; avoid driving until you know how it affects you.,Store securely away from children and others; dispose of unused medication properly.,Common side effects: constipation, nausea, dizziness, drowsiness.,Contact doctor if you experience shallow breathing, severe drowsiness, or difficulty waking up.